Biocon · NSE: BIOCON · BSE: 532523
Q2 FY25 results · Jul–Sep 2024
Biocon reported revenue from operations of ₹3,590.40 crore (up 3.7% from Q2 FY24) and net profit of ₹27.10 crore (down 84.3% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,590.40 | 3,462.30 | +3.7% | 3,432.90 | +4.6% |
| Other income | 32.50 | 157.90 | −79.4% | 1,134.50 | −97.1% |
| Total income | 3,622.90 | 3,620.20 | +0.1% | 4,567.40 | −20.7% |
| Profit before tax | 98.40 | 238.50 | −58.7% | 1,145.50 | −91.4% |
| Net profit for the period | 27.10 | 172.70 | −84.3% | 861.80 | −96.9% |
| Attributable to shareholders of the company | (16.00) | 125.60 | Turned loss | 659.70 | Turned loss |
| EPS, basic (₹) | (0.13) | 1.05 | Turned loss | 5.51 | Turned loss |
| Net margin (%) | 0.8 | 5.0 | 25.1 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 525.40 | 518.70 | +1.3% | 510.60 | +2.9% |
| Other income | 73.50 | 69.60 | +5.6% | 41.90 | +75.4% |
| Total income | 598.90 | 588.30 | +1.8% | 552.50 | +8.4% |
| Profit before tax | 20.90 | 46.00 | −54.6% | 1.10 | 19x |
| Net profit for the period | 3.20 | 34.70 | −90.8% | 0.90 | +255.6% |
| EPS, basic (₹) | 0.03 | 0.29 | −89.7% | 0.01 | +200.0% |
| Net margin (%) | 0.6 | 6.7 | 0.2 |
Consolidated
- Filed with BSE
- 30 Oct 2024, 23:23 IST
- Board meeting
- 30 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2024, 23:23 IST
- Board meeting
- 30 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE